Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer

Clinical Trial Description


Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

NCT number NCT00207116
Study type Interventional
Source Eli Lilly and Company
Status Completed
Phase Phase 1
Start date September 2005
Completion date March 2006

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02864394 - Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033) Phase 3
Completed NCT01953913 - Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation Phase 3
Recruiting NCT02847377 - A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC Early Phase 1
Recruiting NCT02926768 - Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT02934360 - TR(ACE) Assay Clinical Specimen Study N/A
Completed NCT01160744 - A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) Phase 2
Active, not recruiting NCT01860898 - A Phase I Study of iPS Cell Generation From Patients With COPD N/A
Active, not recruiting NCT00921310 - Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer Phase 1/Phase 2
Completed NCT01022671 - Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy Phase 2
Completed NCT00932893 - An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene Phase 3
Active, not recruiting NCT00690963 - Individual Boosting in Non-Small Cell Lung Cancer Using Hypofractionation, Intensity-modulated Radiation Therapy and Respiratory Gating Phase 1/Phase 2
Recruiting NCT00797238 - DNA Repair Genes and Outcomes in Patients With Stage III NSCLC N/A
Terminated NCT00558922 - A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT00535275 - NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy Phase 3
Terminated NCT00539331 - Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients Phase 1
Terminated NCT00532025 - Sorafenib in Resected Non-small Cell Lung Carcinoma Phase 2
Completed NCT00531401 - Study of Salirasib to Treat Non-Small Cell Lung Cancer Phase 2
Completed NCT00600587 - Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC) Phase 2
Terminated NCT00558636 - A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) Phase 3
Completed NCT02182102 - Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer Phase 1